PS
GMAB icon

Principal Securities’s Genmab GMAB Stock Holding History

Principal Securities’s Portfolio GMAB Stock Details GMAB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-2,730
Closed -$83.7K – 2226
2025
Q3 		$83.7K Buy
2,730
+499
+22% +$12.2K ﹤0.01% 1673
2025
Q2 		$46.1K Sell
2,231
-436
-16% -$8.95K ﹤0.01% 1928
2025
Q1 		$55.7K Hold
2,667
– – ﹤0.01% 1711
2024
Q4 		$55.7K Sell
2,667
-947
-26% -$20.8K ﹤0.01% 1711
2024
Q3 		$88.1K Buy
3,614
+509
+16% +$13.6K ﹤0.01% 1458
2024
Q2 		$78K Buy
3,105
+359
+13% +$10.2K ﹤0.01% 1422
2024
Q1 		$82.1K Buy
2,746
+316
+13% +$9.28K ﹤0.01% 1362
2023
Q4 		$77.4K Buy
+2,430
New +$76.3K ﹤0.01% 1289

Other funds holding GMAB

OAG
Orbis Allan Gray Hamilton, Bermuda $23.7B AUM 65.43% 1-Year Est. Return
AllianceBernstein
AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Arrowstreet Capital
Arrowstreet Capital Boston, Massachusetts $185B AUM 39.58% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
HL
Harding Loevner Bridgewater, New Jersey $9.72B AUM 22.38% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
First Trust Advisors
First Trust Advisors Wheaton, Illinois $140B AUM 27.84% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Principal Securities's GMAB Position: Q4 2025 in Review

Principal Securities sold out of Genmab (GMAB) in Q4 2025, closing a stake of 2,730 shares — an estimated $83.7K sold.

Principal Securities first reported a position in GMAB in Q4 2023 and held it in 8 quarters. The position peaked at $88.1K in Q3 2024. 292 funds tracked by Wall St. Rank hold GMAB as of Q4 2025.

  • Principal Securities reported no remaining Genmab position as of Q4 2025 after selling out during the quarter.
  • Principal Securities sold 2,730 Genmab shares in Q4 2025, an estimated $83.7K.
  • Principal Securities first reported a position in Genmab in Q4 2023 and held it in 8 quarters.
  • Principal Securities's Genmab position peaked at $88.1K in Q3 2024.
  • 292 funds tracked by Wall St. Rank held Genmab as of Q4 2025.

Based on Principal Securities's 13F filing for Q4 2025, filed 12 Feb 2026.